Tesu Health to Present Clinical Trial Results at ATTD 2025
Tesu Health is pleased to announce its participation in the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025), taking place 19–22 March 2025 in Amsterdam, The Netherlands.
At ATTD 2025, we will present the results of our TH001_1001 clinical trial, a prospective, randomised, controlled study evaluating the impact of PreDiaWell (TH-001) in combination with standard care versus standard care alone in adults with prediabetes. The study aimed to assess the effectiveness of PreDiaWell in improving glycaemic control and supporting weight loss over a 90-day treatment period.
The findings demonstrated that PreDiaWell led to significant reductions in HbA1c, body weight, and BMI, reinforcing its potential as a safe and effective digital therapeutic for individuals at risk of type 2 diabetes. Notably, HbA1c reduction correlated with exposure to PreDiaWell, and no device-related adverse effects were reported.
📢 Presentation Details:
🗓 Date: 20 March 2025
⏰ Time: 10:05 CET
📍 Session: Short Oral Session 05
We are excited to share these important results with the global diabetes research community and explore how digital therapeutics can play a transformative role in preventing diabetes and improving metabolic health. If you are attending ATTD 2025, we invite you to join our session to learn more and connect with our team.